Author:
Afshar Majid,Graham Linck Emma J.,Spicer Alexandra B.,Rotrosen John,Salisbury-Afshar Elizabeth M.,Sinha Pratik,Semler Matthew W.,Churpek Matthew M.
Abstract
Objective
A trial comparing extended-release naltrexone and sublingual buprenorphine-naloxone demonstrated higher relapse rates in individuals randomized to extended-release naltrexone. The effectiveness of treatment might vary based on patient characteristics. We hypothesized that causal machine learning would identify individualized treatment effects for each medication.
Methods
This is a secondary analysis of a multicenter randomized trial that compared the effectiveness of extended-release naltrexone versus buprenorphine-naloxone for preventing relapse of opioid misuse. Three machine learning models were derived using all trial participants with 50% randomly selected for training (n = 285) and the remaining 50% for validation. Individualized treatment effect was measured by the Qini value and c-for-benefit, with the absence of relapse denoting treatment success. Patients were grouped into quartiles by predicted individualized treatment effect to examine differences in characteristics and the observed treatment effects.
Results
The best-performing model had a Qini value of 4.45 (95% confidence interval, 1.02–7.83) and a c-for-benefit of 0.63 (95% confidence interval, 0.53–0.68). The quartile most likely to benefit from buprenorphine-naloxone had a 35% absolute benefit from this treatment, and at study entry, they had a high median opioid withdrawal score (P < 0.001), used cocaine on more days over the prior 30 days than other quartiles (P < 0.001), and had highest proportions with alcohol and cocaine use disorder (P ≤ 0.02). Quartile 4 individuals were predicted to be most likely to benefit from extended-release naltrexone, with the greatest proportion having heroin drug preference (P = 0.02) and all experiencing homelessness (P < 0.001).
Conclusions
Causal machine learning identified differing individualized treatment effects between medications based on characteristics associated with preventing relapse.
Publisher
Ovid Technologies (Wolters Kluwer Health)